By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


SEARCH JOBS

Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.

YEAR FOUNDED:

September 2, 2003

LEADERSHIP:

Founder: Charles Homcy and David Philips

CEO: William Lis

CFO: Mardi Dier

CTO: R. Andrew Ramelmeier

JOBS:

Please click here for Portola job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW PORTOLA:



Key Statistics


Email: info@portola.com
Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA
 




Segment
Start Up





Company News
Portola (PTLA) Announces Andexxa (Andexanet Alfa) Biologics License Application Resubmission Accepted For Review By U.S. FDA 8/15/2017 7:39:02 AM
Portola (PTLA) Reports Second Quarter 2017 Financial Results And Provides Corporate Update 8/10/2017 12:46:40 PM
Portola (PTLA) Announces Resubmission Of Biologics License Application For AndexXa (Andexanet Alfa) 8/4/2017 7:57:50 AM
Portola (PTLA) Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 7/28/2017 10:30:56 AM
Bay Area's Portola (PTLA) Rockets as the FDA Approves First and Only Anticoagulant for Hospitals 6/26/2017 7:04:47 AM
Portola (PTLA) Presents Interim Phase IIa Safety And Efficacy Data For Cerdulatinib At The International Congress Of Malignant Lymphoma 6/15/2017 7:35:30 AM
Portola (PTLA) Reports First Quarter 2017 Financial Results And Provides Corporate Update 6/12/2017 3:16:56 PM
Portola (PTLA) To Announce First Quarter 2017 Financial Results And Host Conference Call On Monday, May 8 5/1/2017 10:38:16 AM
Portola (PTLA) Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update 3/1/2017 10:33:10 AM
Portola (PTLA) To Announce Fourth Quarter And Year-End 2016 Financial Results And Host Conference Call On Tuesday, February 28 2/21/2017 10:46:22 AM
12345678910...
//-->